International Journal for Parasitology: Drugs and Drug Resistance
Toxoplasma gondii is an obligate intracellular parasite with global incidence. The acute infection, toxoplasmosis, is treatable but current regimens have poor host tolerance and no cure has been found for latent infections. This work builds upon a previous high throughput screen which identified benzoquinone acyl hydrazone (KG8) as the most promising compound; KG8 displayed potent in vitro activity against T. gondii but only marginal in vivoefficacy in a T. gondii animal model. To define the potential of this new lead compound, we now describe a baseline structure-activity relationship for this chemotype. Several derivatives displayed IC50's comparable to that of the control treatment pyrimethamine with little to no cytotoxicity. The best of these, KGW44 and KGW59, had higher metabolic stability than KG8. In an in vivo T. gondii murine model, KGW59 significantly increased survivorship. This work provides new insights for optimization of this novel chemotype.
Sanford, A. G.; Schulze, T. T.; Potluri, L. P.; Watson, G. F.; Darner, E. B.; Zach, S. J.; Hemsley, R. M.; Wallick, A. I.; Warner, R. C.; Charman, S. A.; Wang, X.; Vennerstrom, J. L.; and Davis, P. H., "Derivatives of a benzoquinone acyl hydrazone with activity against Toxoplasma gondii" (2018). Biology Faculty Publications. 100.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Funded by the University of Nebraska at Omaha Open Access Fund